Aldeyra Therapeutics Inc. has expanded its novel reactive aldehyde species (RASP) modulator pipeline with the discovery and advancement of new RASP modulators for the treatment of inflammatory and metabolic diseases.
Flagship Pioneering Inc. and Profound Therapeutics Inc., a Flagship-founded company, have announced a collaboration to conduct foundational research to identify potential next-generation first-in-class therapies for the treatment of obesity.
Ventyx Biosciences Inc. has released promising preclinical data for its CNS-penetrant NLRP3 inhibitor VTX-3232 in murine diet-induced obesity (DIO) models.
Researchers from the University of Chicago and Northwestern University have filed for protection of an mobile application to track individualized patient needs, engagement in continuous positive airway pressure machine use, and the correlation of risk behaviors to determine sleep apnea treatment progress.
Tetra Pharm Technologies ApS and Kvanctify ApS have entered into a strategic partnership to accelerate the identification and development of novel drug candidates targeting the endocannabinoid system.
Sixpeaks Bio AG has emerged from stealth with $30 million in series A financing and a pipeline of therapies for healthy weight loss, including a dual-specific antibody targeting activin type IIA and B receptors for preservation of skeletal muscle mass.
Shionogi & Co. Ltd. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of obesity and diabetes type 2.
Obesity is a chronic disorder tied to other disorders such as hyperglycemia, type 2 diabetes or cardiovascular disease, among others. Recent findings have suggested that EphB tyrosine kinase receptor and its ligand, ephrin B, may be involved in insulin signaling.
In a potential watershed moment for South Korea’s Hanmi Group, a hair-splitting vote at the 51st shareholder meeting favored the two sons of the late founder and Chairman Lim Sung-ki, effectively halting a merger between Hanmi and OCI Holdings Co. Ltd.
